Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial

Royce M., BACHELOT T., VILLANUEVA C., Ozguroglu M., AZEVEDO S. J., CRUZ F. M., ...Daha Fazla

JAMA ONCOLOGY, cilt.4, sa.7, ss.977-984, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 4 Sayı: 7
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1001/jamaoncol.2018.0060
  • Dergi Adı: JAMA ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.977-984
  • İstanbul Üniversitesi Adresli: Evet

Özet

IMPORTANCE Cotargeting the mammalian target of rapamycin pathway and estrogen receptor may prevent or delay endocrine resistance in patients receiving first-line treatment for advanced breast cancer.